Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1241-1242

  Spadaro, A ^a   Riccieri, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 23444452225     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.032136     Document Type: Article

References (4)

1. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffmann IEA, Veys EM, et al. Rheumatoid factor, but not anti-citrullinated protein antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64: 299-302 doi, 10.1136/ard.2004.023523 [published Online First: 27 May 2004].
2. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco M. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004;6: R264-72, Epub 26 April, 2004.
3. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.
4. Spadaro A, Riccieri V, Sili Scavalli A, Taccari E, Zoppini A. One year treatment with low dose methotrexate in rheumatoid arthritis: effect on class specific rheumatoid factors. Clin Rheumatol 1993;12:357-60.